NEW YORK (GenomeWeb News) – Cepheid said after the close of the market Wednesday that it expects to report third-quarter revenues of between $79 million and $81 million, below its own target range and Wall Street's average estimate of $83.8 million.

The Sunnyvale, Calif.-based firm said the shortfall is due to "intermittent interruptions in the supply of Xpert cartridge parts." The Xpert cartridges contain the tests that run on the firm's GeneXpert systems.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.